Mutation status and surgical selection

Georgios A. Margonis, Martin E. Kreis, Christopher L. Wolfgang, Matthew J Weiss

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Current evidence cannot support denying metastasectomy in otherwise resectable patients solely based on their overall KRAS or BRAF mutational status. The combination of KRAS or BRAF mutational status with certain clinicopathologic characteristics has defined groups of patients who may not derive benefit from metastasectomy, but external validation is needed. The effect of certain KRAS or BRAF variants on survival may be more pronounced and therefore future studies should consider them for surgical selection.

Original languageEnglish (US)
JournalJournal of Surgical Oncology
StatePublished - Jan 1 2019


  • BRAF
  • KRAS
  • metastasectomy
  • metastatic colorectal cancer
  • somatic mutations

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'Mutation status and surgical selection'. Together they form a unique fingerprint.

Cite this